Long Ideas - ChemoCentryx (CCXI), which we originally recommended on August 5 as a play on upcoming Phase III data for the company’s lead drug candidate vercirnon, has … Continue Reading
Read nowLong Ideas - BioLife Solutions, the Bothell, WA based supplier of biopreservation media products and contract manufacturer, has climbed over 100% since our April report on the company. … Continue Reading
Read nowInsights - ChemoCentryx (CCXI) announced on Friday before the open that the Phase III SHIELD-1 study, testing the chemokine receptor inhibitor vercirnon in patients with moderate-to-severe Crohn’s … Continue Reading
Read nowLong Ideas - Since we initiated coverage of Cubist Pharmaceuticals (CBST) in mid-May, shares of the antibiotics manufacturer are up over 26%, as the company secured a key … Continue Reading
Read nowLong Ideas - Regeneron Pharmaceuticals (REGN), due in large part to the continued growth of Eylea, has become the world’s 5th largest biotechnology company by market capitalization. Regeneron, … Continue Reading
Read nowLong Ideas - Since making their public debut in February 2012, shares of ChemoCentryx (CCXI) have risen less than 23%, underperforming the NASDAQ Biotechnology Index’s nearly 64% rise … Continue Reading
Read nowLong Ideas - Shares of Alexion Pharmaceuticals (ALXN) have seen a choppy 2013 as concerns over Soliris supply and growth met rumors that Roche (RHHBY) was seeking to … Continue Reading
Read now